Literature DB >> 15712655

Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

Yoshitaka Ueno1, Shinji Tanaka, Masaru Shimamoto, Yoshihiro Miyanaka, Toru Hiyama, Masanori Ito, Yasuhiko Kitadai, Masaharu Yoshihara, Masaharu Sumii, Kazuaki Chayama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15712655     DOI： 10.1007/s10620-005-1295-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  14 in total

Review 1.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Authors:  W J Sandborn; S B Hanauer
Journal:  Inflamm Bowel Dis       Date:  1999-05       Impact factor: 5.325

2.  Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

Authors:  P Ostuni; C Botsios; L Punzi; P Sfriso; S Todesco
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

Review 3.  Review article: safety of infliximab in clinical trials.

Authors:  S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  1999-09       Impact factor: 8.171

4.  Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection.

Authors:  S Campbell; S Ghosh
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-02       Impact factor: 2.566

5.  HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines.

Authors:  J F Schlaak; G Tully; H F Löhr; G Gerken; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

6.  Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures.

Authors:  Valérie Pasquetto; Stefan F Wieland; Susan L Uprichard; Marco Tripodi; Francis V Chisari
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

Authors:  Marc Michel; Cristophe Duvoux; Cristophe Hezode; Daniel Cherqui
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

9.  Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

Authors:  Owonayo Oniankitan; Christophe Duvoux; Dominique Challine; Arianne Mallat; Xavier Chevalier; Jean-Michel Pawlotsky; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

10.  Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Authors:  J R Peterson; F C Hsu; P A Simkin; M H Wener
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103
View more
  15 in total

1.  Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

Authors:  Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

Review 2.  Infliximab-related hepatitis: a case study and literature review.

Authors:  Francisco Colina; Aída Molero; Begoña Casís; Pilar Martínez-Montiel
Journal:  Dig Dis Sci       Date:  2013-05-05       Impact factor: 3.199

3.  Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial.

Authors:  Ohad Etzion; Victor Novack; Yael Perl; Olga Abel; Doron Schwartz; Daniella Munteanu; Naim Abufreha; Gil Ben-Yaakov; Eyal D Maoz; Alex Moshaklo; Vitaly Dizingf; Alex Fich
Journal:  J Crohns Colitis       Date:  2016-02-29       Impact factor: 9.071

Review 4.  Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Authors:  María Rojas-Feria; Manuel Castro; Emilio Suárez; Javier Ampuero; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 5.  Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Authors:  Matthew B Carroll; Michael A Forgione
Journal:  Clin Rheumatol       Date:  2010-06-16       Impact factor: 2.980

Review 6.  Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

Authors:  Pilar López-Serrano; Jose Lázaro Pérez-Calle; Maria Dolores Sánchez-Tembleque
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

7.  Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab.

Authors:  Keisuke Ojiro; Makoto Naganuma; Hirotoshi Ebinuma; Hiroyoshi Kunimoto; Shinichiro Tada; Haruhiko Ogata; Yasushi Iwao; Hidetsugu Saito; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

Review 8.  Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature.

Authors:  Takeshi Kuroda; Yoko Wada; Daisuke Kobayashi; Hiroe Sato; Syuichi Murakami; Masaaki Nakano; Ichiei Narita
Journal:  Rheumatol Int       Date:  2010-01-09       Impact factor: 2.631

Review 9.  Hepatitis C virus and inflammatory bowel disease.

Authors:  Todd L Horn; Joel Reynolds; Willem de Villiers; Luis R Peña
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

Review 10.  Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.

Authors:  Stefano Sansone; Maria Guarino; Fabiana Castiglione; Antonio Rispo; Francesco Auriemma; Ilaria Loperto; Matilde Rea; Nicola Caporaso; Filomena Morisco
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.